MarketMoodz
Raymond James Adds UNH and JANUS Living to Top Healthcare Picks
Raymond James upgraded its top healthcare list by adding UnitedHealth Group (UNH) and JANUS Living (JANUS), replacing Oscar Health. The move favors dividend-paying, defensive names after UNH’s strong quarter and Janus’s post-IPO rally, signaling the firm’s preference for earnings momentum and income in healthcare.
Key Takeaways
- UnitedHealth beat Q1 estimates with adjusted EPS $7.23 and revenue $111.72 billion, and raised full-year adjusted EPS guidance to $18.25 from $17.75.
- UNH raised its quarterly dividend 5% to $2.32 per share, giving a dividend yield of about 2.2%, and the stock is roughly 28% YTD in 2026.
- JANUS Living, which IPO'd at $20 in March (implied valuation ~$840M), closed at $28.99—about 45% above the IPO price—and yields roughly 1.96%.
- Analyst sentiment is bullish: about 24 of 30 rate UNH buy/strong buy (consensus price target implies ~3% downside), and roughly 10 of 11 rate Janus buy/strong buy (consensus implies ~3% upside).
- Raymond James cites improving margins, seniors-housing recovery, favorable demographics, limited new supply, and potential acquisitions as the thesis for Janus and expects continued outperformance from UNH.
People Involved
- No specific individuals mentioned
Entities Involved
- Raymond JamesBroker-dealer issuing the healthcare top-picks note
- UnitedHealth Group (UNH)Large insurer and payer; added to Raymond James' top healthcare picks
- JANUS Living (JANUS)Senior-housing REIT; newly public company added to the list
- Oscar HealthReplaced on Raymond James' list by UnitedHealth
- UBSMarket commentator noting global healthcare’s increased appeal
MarketMoodz Analysis
For investors, Raymond James’ update is a vote for defensive, income-oriented healthcare exposure after a period of sector outperformance: UNH reported a beat in Q1 (adjusted EPS $7.23 versus $6.58 consensus) and lifted full-year guidance to $18.25, while raising its quarterly dividend 5% to $2.32. That combination—earnings upside, stronger guidance and a higher payout—supports the case for UNH as a core holding in risk-managed portfolios, especially with the stock up roughly 28% YTD in 2026.
JANUS Living gives investors a healthcare-adjacent real-estate play: it IPO'd at $20 in March with an implied valuation near $840 million and closed at $28.99 (≈+45% from IPO). Raymond James points to improving margins, a seniors-housing portfolio recovery, favorable demographics, limited new supply and potential M&A as drivers. For income-focused allocations, JANUS’s ~1.96% yield plus mid-teens post-IPO upside reflects investor appetite for niche REITs that benefit from secular aging demographics.
What to watch next: UNH’s upcoming earnings print (around July 16) and any further guidance shifts will be immediate catalysts; sector-level metrics—medical-cost trends, margin revisions and regulatory updates—remain the primary macro risks. Investors should also note the limitations: the Raymond James note is a broker-dealer publication, some third-party numbers (analyst targets, Janus valuation) should be cross-checked against filings, and reimbursement or policy changes could materially alter payers’ profitability.
Source: Original Article